Flags

Financial distress

Regenxbio

NSQ:RGNX · US75901B1070

BiotechnologySmall

360

Value39

Profit price15

Cash yield1

Sales & asset price92

Price/Sales100

Price/Book83

Quality31

Returns on capital19

Return on Capital31

Cash Return on Capital16

Return on Equity11

Profit margins5

EBIT Margin6

Gross Profitability4

Cash backing47

Accruals67

Owner Earnings Margin27

Growth51

Sales growth77

Profit growth43

Reinvestment13

Price momentum10

Safety32

Debt load5

Debt serviceability14

Refinancing27

Debt Payback1

Liquidity95

Sentiment58

Analyst ratings15

Expectations trend75

Opinion Changes50

Price Target Upside100

Market mood51

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Regenxbio doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2008

Employees318

Websiteregenxbio.com

ISINUS75901B1070

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

OphthalmologyNeurologyGeneticsCentral Nervous SystemNeuroscienceGenetic DisorderBiotechnologyHealth Care

Description

REGENXBIO Inc. (‘REGENXBIO’) operates as a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The company’s investigational gene therapies are designed to deliver functional genes to address…

Analysis

Weak and unloved

REGENXBIO Inc. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

100

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Regenxbio with its peers

Tenaya Therapeutics

NSQ:TNYA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Taysha Gene Therapies

NSQ:TSHA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Voyager Therapeutics

NSQ:VYGR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Benitec Biopharma

NAQ:BNTC

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Palvella Therapeutics

NAQ:PVLA

100

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Prelude Therapeutics

NSQ:PRLD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →